DR. ANTON E. SCHRAFL

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

ABRDN ASIA-PACIFIC INCOME FUND, INC.

Filing Date Source Excerpt
2002-01-30 Dr. Anton E. Schrafl Dr. Schrafl is currently Deputy Chairman of Holcim 70 1998 0 Limited, a global manufacturer and distributor of cement and allied products. He also serves on the Board of Directors of Organogenesis, Inc., a medical products company involved in biotechnological tissue engineering, and Apogee Technology Inc., a manufacturer of digital amplifiers. Director, Aberdeen Commonwealth Income Fund, Inc. (since 1993); Director, Aberdeen Asia-Pacific Income Investment Company Limited.
2003-02-20 Dr. Anton E. Schrafl Wiesenstrasse 7 8008 Zurich Switzerland Age: 70 Preferred Stock Director Current term expires 2003; Director since 1998 Dr. Schrafl was Deputy Chairman of Holcim Limited, a global manufacturer and distributor of cement and allied products until May 2002. He currently serves as Chairman of the Board of Directors of Dynavest, AG, a corporation focusing on investments. Dr. Schrafl is also on the Board of Directors of Organogenesis, Inc., a medical products company involved in biotechnological tissue engineering, and Apogee Technology Inc., a manufacturer of digital amplifiers.
2004-03-24 Dr. Schrafl was Deputy Chairman of Holcim Limited, a global manufacturer and distributor of cement and allied products until May 2002. He currently serves as Chairman of the Board of Directors of Dynavest, Ltd., an investment management company. Until 2003, Dr. Schrafl served on the Board of Directors of Organogenesis, Inc., a medical products company involved in biotechnological tissue engineering, and Apogee Technology Inc., a manufacturer of digital amplifiers.
2005-03-18 Dr. Schrafl has been Chairman of the Board of Dynavest Ltd. since 1993. He is a Preferred Stock Director. He received $39,990 in total compensation for the fiscal year ended October 31, 2004.
2006-01-30 Dr. Anton E. Schrafl ... Age: 74 ... Preferred Stock Director ... Dr. Schrafl has been Chairman of the Board of Dynavest Ltd.(investment management company) since 2002. ... Compensation Table Fiscal Year Ended October 31, 2005 ... Dr. Anton E. Schrafl ... Total Compensation From Fund and Fund Complex Paid to Directors* ... $42,500
2007-02-14 Dr. Anton E. Schrafl Wiesenstrasse 7 CH-8008 Zurich Switzerland Date of Birth: January 8, 1932 Preferred Stock Director/Nominee Current term expires 2007; Director since 1998 Dr. Schrafl has been Chairman of the Board of Dynavest Ltd. since 2002. He was Deputy Chairman of Holcim Limited from 1985 until 2002. Total Compensation From Fund and Fund Complex Paid to Directors: $49,417.
2008-02-19 Dr. Anton E. Schrafl†† Preferred Director ... The terms of Mr. Aaronson and Dr. Anton E. Schrafl will expire at the 2008 Annual Meeting of Stockholders ... Total Compensation From Fund and Fund Complex Paid to Directors: $53,500

ABRDN GLOBAL INCOME FUND, INC.

Filing Date Source Excerpt
2002-01-30 Dr. Anton E. Schrafl Dr. Schrafl is currently Deputy Chairman of Holcim Limited... Preferred Directors: Dr. Anton E. Schrafl.... $14,000 N/A N/A $32,375(2)
2004-03-24 Dr. Schrafl was Deputy Chairman of Holcim Limited, a global manufacturer and distributor of cement and allied products until May 2002. He currently serves as Chairman of the Board of Directors of Dynavest Ltd., an investment management company. Until 2003, Dr. Schrafl served on the Board of Directors of Organogenesis, Inc., a medical products company involved in biotechnological tissue engineering, and Apogee Technology Inc., a manufacturer of digital amplifiers.
2005-03-18 Dr. Anton E. Schrafl Wiesenstrasse 78008 ZurichSwitzerland Age: 73 Preferred Stock Director Current term expires 2005; Director since 1993 Dr. Schrafl has been Chairman of the Board of Dynavest Ltd., (investment management company) since 1993. He was Deputy Chairman of Holcim Limited (global manufacturer and distributor of cement and allied products) from 1985 until 2002. 2 Aberdeen Asia-Pacific Income Fund, Inc. Mr. Sheehy is a member of the Contract Review Committee. The following table sets forth information regarding compensation of Directors by the Fund and by the fund complex of which the Fund is a part for the fiscal year ended October 31, 2004. Each Independent Director of the Fund receives an aggregate fee, effective January 1, 2004, of $18,500 per year, inclusive of attendance at in-person and telephonic Board meetings. Members of the Fund’s Audit and Valuation Committee, Contract Review Committee, Nominating and Corporate Governance Committee and ad hoc committees receive a fee of $500 per committee meeting attended, and the Chairman of each of these Committees receives an additional fee of $500 per committee meeting attended. The fees for attendance at committee meetings may be less than $500 per meeting, in certain instances where committee meetings are held jointly with committee meetings of other funds in the same fund complex. Dr. Anton E. Schrafl Aggregate Compensation From Fund $17,390 Total Compensation From Fund and Fund Complex Paid to Directors $39,990
2006-01-27 Dr. Anton E. Schrafl Wiesenstrasse 7 CH - 8008 Zurich Switzerland Age: 74 Preferred Stock Director Current term expires 2006; Director since 1993 Dr. Schrafl has been Chairman of the Board of Dynavest Ltd. (investment management company) since 2002. He was Deputy Chairman of Holcim Limited (global manufacturer and distributor of cement and allied products) from 1985 until 2002. 2 Aberdeen Asia-Pacific Income Fund, Inc. Mr. Sheehy is a member of the Audit and Valuation Committee. During the fiscal year ended October 31, 2005: each Independent Director of the Fund received an aggregate fee of $18,500 per year, inclusive of attendance at in-person and telephonic Board meetings; members of the Board’s Audit and Valuation Committee, Contract Review Committee, Nominating and Corporate Governance Committee and ad hoc committees received a fee of $500 per committee meeting attended, and the Chairman of each of these Committees received an additional fee of $500 per committee meeting attended. The fees for attendance at committee meetings may have been less than $500 per meeting, in certain instances where committee meetings were held jointly with committee meetings of other funds in the same fund complex. The following table sets forth information regarding compensation of Directors by the Fund and by the fund complex of which the Fund is a part for the fiscal year ended October 31, 2005. Officers of the Fund and Directors who are interested persons of the Fund do not receive any compensation directly from the Fund or any other fund in the fund complex for performing their duties as officers or Directors, respectively. During the fiscal year ended October 31, 2005: each Independent Director of the Fund received an aggregate fee of $18,500 per year, inclusive of attendance at in-person and telephonic Board meetings; members of the Board’s Audit and Valuation Committee, Contract Review Committee, Nominating and Corporate Governance Committee and ad hoc committees received a fee of $500 per committee meeting attended, and the Chairman of each of these Committees received an additional fee of $500 per committee meeting attended. The fees for attendance at committee meetings may have been less than $500 per meeting, in certain instances where committee meetings were held jointly with committee meetings of other funds in the same fund complex. In December 2005, the Board of Directors, upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved the following fee structure, effective January 1, 2006: Each Independent Director will receive a retainer fee of $19,000 per year and a fee of $1,500 per meeting for attendance at Board meetings. In addition, the Chairman of the Board will receive a fee of $10,000 per year, the Chairman of the Contract Review Committee will receive a fee of $5,000 per year, and the Chairman of the Audit and Valuation Committee will receive a fee of $5,000 per year.
2007-02-14 Dr. Anton E. Schrafl Wiesenstrasse 7 CH - 8008 Zurich Switzerland Date of Birth: January 8, 1932 Preferred Stock Director/ Nominee Current term expires 2007; Director since 1993 Dr. Schrafl has been Chairman of the Board of Dynavest Ltd. (investment management company) since 2002. He was Deputy Chairman of Holcim Limited (global manufacturer and distributor of cement and allied products) from 1985 until 2002. Compensation Table Fiscal Year Ended October 31, 2006 Dr. Anton E. Schrafl $ 0 $ 23,417 N/A N/A $ 0 $ 49,417 (2)
2008-02-19 Each Independent Director of the Fund receives a retainer fee of $19,000 per year and a fee of $1,500 per meeting for attendance at Board meetings. ... The members of the Fund's Audit and Valuation Committee are Messrs. David L. Elsum, Peter D. Sacks, John T. Sheehy and Warren C. Smith. ... The terms of Messrs. Elsum and Scott and of Dr. Schrafl will expire at the 2008 Annual Meeting of Stockholders. ... Total Compensation From Fund and Fund Complex Paid to Directors: $53,500.

Data sourced from SEC filings. Last updated: 2025-12-06